Angiotensin II acetate is a Synthetic Peptide owned by La Jolla Pharmaceutical, and is involved in 9 clinical trials, of which 5 were completed, 3 are ongoing, and 1 is planned.
LJPC-501 acts by agonising angiotensin II type I receptor of the renin-angiotensin system. Angiotensin II is central to the renin-angiotensin system which raises blood pressure. In hepatorenal syndrome, renin-angiotensin system is essential in counteracting arterial hypotension. The drug candidate by agonising angiotensin II type I receptor of the renin-angiotensin system helps the kidneys to balance body fluids and electrolytes and also by causing the vasoconstriction of vessels systemically in hepatorenal syndrome.
The revenue for Angiotensin II acetate is expected to reach a total of $690m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Angiotensin II acetate NPV Report.
Angiotensin II acetate Overview
Angiotensin II acetate (Giapreza) is a naturally occurring peptide hormone derivative act as a vasoconstrictor agent. It is formulated as sterile, aqueous solution and solution concentrate for intravenous route of administration. Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock.
It is under development for hypotension in pediatrics. It was also under development for hepatorenal syndrome (HRS).
Innoviva is a company with a portfolio of royalties. It partners with companies that advance innovative therapies for improving patient care and building long-lasting value. Its operations primarily focus on royalty management. The company has partnership agreements with GSK for the commercialization and development of respiratory products. Its current portfolio includes respiratory assets partnered with Glaxo Group Limited (GSK) for various respiratory disorders. The company’s R&D also focuses on developing innovative formulations for the treatment of respiratory disorders. It receives royalty payments on the sale of these partnered products to clients as per the terms of its agreements with GSK. Innoviva is headquartered in Brisbane, California, the US.
The company reported revenues of (US Dollars) US$391.9 million for the fiscal year ended December 2021 (FY2021), an increase of 16.4% over FY2020. In FY2021, the company’s operating margin was 95.7%, compared to an operating margin of 95.3% in FY2020. In FY2021, the company recorded a net margin of 67.8%, compared to a net margin of 66.6% in FY2020. The company reported revenues of US$108.2 million for the second quarter ended June 2022, an increase of 20.2% over the previous quarter.
Quick View – Angiotensin II acetate
|Highest Development Stage|